Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma

Annals of Surgical Oncology

Volumn 10, Issue 4, 2003, Pages 396-402

  Ribuffo, Diego ^a,d   Gradilone, Angela ^a   Vonella, Marco ^b   Chiummariello, Stefano ^a   Cigna, Emanuele ^a   Haliassos, Nickolaos ^a   Massa, Rita ^a   Silvestri, Ida ^a,c   Calvieri, Stefano ^a   Frati, Luigi ^a   Aglianò, Anna Maria ^a   Scuderi, Nicolò ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Policlinico Mater Domini   (Italy)

^c IRCCS NEUROMED   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

MART 1; Melanoma; Polymerase chain reaction; Sentinel lymph node; Tyrosinase

Indexed keywords

MELANOMA ANTIGEN 1; MONOPHENOL MONOOXYGENASE; MART1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN; TYROSINE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SKIN TUMOR; SURVIVAL;

ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TYROSINE;

EID: 0043163401     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.06.006     Document Type: Article

References (35)

1. Armstrong SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Buzaid AC, Tinoco LA, Iendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995;13:2361-8.
3. Morton DL, Wanwk L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491-9.
4. Clark WHJ, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
5. Worth AJ, Gallagher RP, Elwood JM, et al. Pathologic prognostic factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Int J Cancer 1989;43:370-5.
6. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992;8:400-14.
7. Balch CM, Soong S, Shaw HM, Urist MM, McCarthy SW. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, ed. Cutaneous Melanoma. Philadelphia: Lippincott, 1992:165-87.
8. Gamel JW, George SL, Stanley WE, Seigler HF. Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex. Cancer 1993;72:1219-23.
9. Thorn M, Ponten F, Bergstrom R, Sparen F, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86:761-9.
10. Miliotes C, Lyman GH, Crune CW, et al. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 1996;3: 558-63.
11. Morton DL, Wen DR, Cochran AP. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin North Am 1992;1:247-59.
12. Morton DL, Wen DR, Foshag LJ, et al. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993;11:1751-6.
13. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998;16:2632-40.
14. Ludwig Trial, International Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
15. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid-guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
16. Campbell MJ, Gerdner MJ. Calculating confidence intervals for some nonparametric analyses. BMJ 1988;296:1454-6.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Cox D. Regression models and life tables. J R Stat Soc B 1972; 34:187-201.
19. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer-Verlag, 1997.
20. Wang X, Heller R, Van Voorthis N, et al. Detection of submicroscopic lymph node metastases with PCR in patients with malignant melanoma. Ann Surg 1994;220:768-74.
21. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early stage melanoma patients. J Clin Oncol 1999;17:3238-44.
22. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280: 1410-5.
23. Blaheta HJ, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;114:637-42.
24. Sung J, Li W, Shivers S, Reintgen D. Molecular analysis in evaluating the sentinel node in malignant melanoma. Ann Surg Oncol 2001;8(9 Suppl):29S-30S.
25. Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma: past, present, and future. Ann Surg Oncol 2001;8(9 Suppl):22S-28S.
26. Cochran AJ, Huang RR, Guo J, Wen DR. Current practice and future directions in pathology and laboratory evaluation of the sentinel node. Ann Surg Oncol 2001;8(9 Suppl):13S-17S.
27. van der Velde-Zimmermann D, Schipper ME, de Weger RA, et al. Sentinel node biopsies in melanoma patients: a protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol 2000;7:51-4.
28. Blaheta HJ, Sotlar K, Breuninger H, et al. Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma? Melanoma Res 2001;11:57-63.
29. Hoon DS, Okamoto T, Wang HJ, et al. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol 1998;16:1430-7.
30. Morton DL, Wen DR, Wong JR, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
31. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280: 1410-5.
32. Chi DD, Merchant RE, Rand R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997;150:2143-52.
33. Blaheta HJ, Schittek B, Breuninger H, et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999;23:822-8.
34. Blaheta HJ, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;114:637-42
35. Clary BM, Mann B, Brady MS, Lewis JJ, Coit DG. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001;8:328-37.